Everest Medicines

News

18 2022/07

Everest Medicines Announces European Commission Grants Approval of Kinpeygo^® for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics
10 2022/06

Everest Medicines Announces Approval of Trodelvy^® in China for Second-Line Metastatic Triple-Negative Breast Cancer
04 2022/06

Everest Medicines’ Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy^® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
24 2022/05

Everest Medicines’ Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis
07 2022/04

Everest Medicines Enters into an MOU for Partnership with China Resources Pharmaceutical Group for its mRNA Vaccine Business
06 2022/04

Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis
31 2022/03

Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
30 2022/03

Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
29 2022/03

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2021
26 2022/03

Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients
15 2022/03

Everest Medicines to Announce Full-Year 2021 Financial Results on March 29, 2022
14 2022/03

Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea

Copyright Everest Medicines 2020 云顶药业（苏州）有限公司苏ICP备20038571号 | Terms of Use | Privacy Policy | Disclaimers

沪公网安备 31010602006477号